


IN THE CLAIMS

The status of the claims is listed below.

Claim 1 (Previously Presented): A compound of the formula (I):




wherein R^1 is hydrogen or lower alkyl;

R^2 is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; lower alkenyl; cycloalkyl; cyano; lower alkanoyl; cycloalkylcarbonyl; N,N-di(lower)alkylcarbamoyl; carbamoyl; N-lower alkoxy-N-lower alkylcarbamoyl; amino; di(lower)alkylamino; lower alkoxy-carbonylamino; N,N-di(lower)alkylcarbamoylamino; N-(N,N-di(lower)alkylcarbamoyl)-N-lower alkylamino; halogen; hydroxy; carboxy; lower alkoxy-carbonyl; aroyl; lower alkylsulfonyl; lower alkoxy optionally substituted with lower alkoxy, N,N-di(lower)alkylcarbamoyl or halogen; cycloalkyloxy; lower alkylthio; or lower alkylsulfinyl;

R^3 is lower alkyl optionally substituted with amino, carbamoylamino or lower alkylsulfonylamino; halogen; cyano; hydroxy; lower alkanoyloxy; lower alkylenedioxy; lower alkoxy optionally substituted with aryl, hydroxy, cyano, amino, lower alkoxy-carbonylamino, lower alkylsulfonylamino or

carbamoylamino; nitro; amino; ~~heterocyclic group~~; lower alkylthio; lower alkylsulfinyl; or lower alkylsulfonyl;

R^4 is a group of the formula:



in which G is -CO-;

J is -N(R^6) -

(wherein R^6 is hydrogen or lower alkyl) ; and

R^5 is amino optionally substituted with lower alkoxy carbonyl or lower alkyl; lower alkyl optionally substituted with hydroxy, lower alkoxy carbonylamino, lower alkanoyloxy, amino or halogen; lower alkoxy; hydrogen; or aryl;

X is O, S, SO or SO₂;

Y is CH;

Z is lower alkylene or lower alkenylene; and

m is 0 or 1;

or a salt thereof.

Claim 2 (Previously Presented): The compound of Claim 1, wherein

R^1 is hydrogen;

R^2 is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; cycloalkyl; halogen; lower alkoxy optionally substituted with halogen; or lower alkylthio;

R^3 is lower alkoxy optionally substituted with aryl, hydroxy, cyano, amino, lower alkoxy carbonylamino, lower alkylsulfonylamino or carbamoylamino;

X is O or S; and

Z is lower alkylene.

Claim 3 (Previously Presented): The compound of Claim 2, wherein

R² is lower alkyl optionally substituted with halogen; cycloalkyl; halogen; or lower alkoxy optionally substituted with halogen;

R³ is lower alkoxy;

J is -NH- and

R⁵ is amino or lower alkyl; and

X is O.

Claim 4 (Currently Amended): The compound of Claim 3, which is

N-(2-(4-[3-chloro-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-phenoxy)ethyl)urea,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-

yl]benzyl)methanesulfonamide,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]benzyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

~~N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,~~

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxyethyl)acetamide, or

N-(2-(4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea.

Claim 5: (Canceled).

Claim 6 (Original): A pharmaceutical composition comprising the compound of Claim 1, as an active ingredient, in association with a pharmaceutically non-toxic carrier or excipient.

Claim 7: (Canceled).


Claim 8 (Previously Presented): A method for treatment of inflammatory conditions, pain, collagen diseases, autoimmune diseases, immunity diseases, analgesic, thrombosis, cancer or neurodegenerative diseases which comprises administering an effective amount of the compound of Claim 1 to a human being or an animals.

Claims 9-12: (Canceled).


Claim 13 (Previously Presented): A method of treating an inflammatory condition, comprising administering an effective amount of the compound of Claim 1 to a human being or an animal.

Claim 14 (Previously Presented): A process of preparing a compound of Claim 1 or a salt thereof, comprising:


1) reacting a compound of the formula:



or a salt thereof with a compound of the formula:




or a salt thereof in the acidic condition to provide a compound of the formula:



or a salt thereof, in the above formulas,

or


2) reacting a compound of the formula:



or a salt thereof with a compound (V) of the formula:



or a salt thereof to provide a compound of the formula:



or a salt thereof,

wherein R¹, R², R³, R⁴, X, Y, Z and m are each as defined in Claim 1,

Xa is O or S, and

Q is hydroxy or an acid residue.

Claim 15 (New): A compound which is N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea or a salt thereof.

Claim 16 (New): The compound of Claim 15, which is a salt thereof.

Claim 17 (New): The compound of Claim 15, which is an alkali metal salt, alkaline earth metal salt, ammonium salt, organic base salt, organic acid salt, an inorganic acid salt or a salt with an amino acid.

Claim 18 (New): The compound of Claim 15, which is N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea.

Claim 19 (New): A pharmaceutical composition comprising the compound of Claim 15, as an active ingredient, in association with a pharmaceutically non-toxic carrier or excipient.

Claim 20 (New): A method for treatment of inflammatory conditions, pain, collagen diseases, autoimmune diseases, immunity diseases, analgesic, thrombosis, cancer or neurodegenerative diseases which comprises administering an effective amount of the compound of Claim 15 to a human being or an animals.

Claim 21 (New): A method of treating an inflammatory condition, comprising administering an effective amount of the compound of Claim 15 to a human being or an animal.